Navigation Links
BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Date:1/10/2008

BIRMINGHAM, Ala., Jan. 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced Thomas J. Simon, M.D. has joined BioCryst as a consultant and interim Chief Medical Officer. Dr. Simon brings more than 20 years of expertise in global pharmaceutical development to his position at BioCryst.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO )

"We are very pleased to have Tom join BioCryst at this important time," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "Tom brings a sound knowledge of systematic, worldwide product development from his tenure at Merck & Co. where he was responsible for moving several key products from the clinical development-stage through to marketing approval. As our programs continue to move forward Tom's expertise in product development will be of immeasurable value."

The Company has undertaken a search to find a permanent successor to Dr. Simon.

Most recently, Dr. Simon held the position of Vice President, Clinical and Quantitative Sciences Administration at Merck & Co. with responsibility as Acting Head of Oncology Clinical Research. During his tenure with Merck & Co, Dr. Simon held various senior clinical positions including responsibility for resource allocation and shared services in Clinical and Quantitative Sciences and Vice President, Gastroenterology Clinical Research. Prior to joining Merck & Co., Dr. Simon held senior clinical positions at William H. Rorer, Inc. of Ft. Washington, Pennsylvania and also at Miles Pharmaceuticals of West Haven, Connecticut.

Dr. Simon received his B.S. and M.S. from Stanford Univers
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. Medpace Strengthens Presence in Central Europe
5. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
6. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
7. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
8. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
9. Anavex strengthens Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... 19, 2011 BioRestorative Therapies, Inc. (OTCQB: BRTX) (the "Company"), ... its common stock is now trading on the OTCQB market ... trading symbol for its common stock has been changed from ... and Chief Executive Officer, said, "The commencement of trading using ...
... Sept. 19, 2011 Palatin Technologies, Inc. (NYSE Amex: ... 2011 financial results on Thursday, September 22, 2011 before the ... also conduct a conference call and live audio webcast hosted ... will include discussion of the results of operations in greater ...
... Sept. 19, 2011 The U.S. Patent and Trademark ... to Cenestra Health,s high-purity omega-3 fatty acid formulations and ... range of high-purity omega-3 formulations including ethyl-ester, free fatty ... was issued U.S. Patent No. 7652068, entitled "Omega-3 ...
Cached Biology Technology:BioRestorative Therapies, Inc. Begins Trading Under New Name and Symbol ("BRTX") 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 3
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... a multi-institutional study led by Cincinnati Childrens Hospital ... stubborn solid tumor cancers neuroblastoma and peripheral ... inserting instructions to inhibit tissue growth into an ... the February 15 Cancer Research. Malignant ...
... a one-celled, planktonic marine organism, reported today (Thursday, ... telling scientists about the evolutionary changes that accompanied ... animals like ourselves. In the Nature paper ... week, University of California, Berkeley, biologists Nicole King, ...
... the ideal environmentally friendly energy source, it would be a ... that does not pollute our air when burned. That is ... in a new program that uses bacteria and sunlight to ... The project is one of the first to ...
Cached Biology News:Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors 2Genome of marine organism tells of humans' unicellular ancestors 2Genome of marine organism tells of humans' unicellular ancestors 3Genome of marine organism tells of humans' unicellular ancestors 4Project focuses on production of hydrogen from bacteria and sunlight 2Project focuses on production of hydrogen from bacteria and sunlight 3Project focuses on production of hydrogen from bacteria and sunlight 4
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Biology Products: